



CSIR-Central Drug Research Institute
(Council of Scientific & Industrial Research)
Sector 10, Jankipuram Extn., Sitapur Road
Lucknow - 226 031, UP, India

CSIR-CDRI Invites Expression of Interest (EOI) for Licensing 'CSIR-CDRI candidate drug: 99/373 to Pharmaceutical Industries

CSIR-Central Drug Research Institute is a constituent laboratory of Council of Scientific & Industrial Research, an autonomous body under Ministry of Science & Technology, Govt. of India. CSIR-CDRI is happy to announce that it has developed the following **New candidate drug for licensing to pharmaceutical industries.**

1. CSIR-CDRI candidate drug: 99/373 for Post-Menopausal Osteoporosis

DCGI permission along with the ethics committee approval obtained for initiating Phase-I clinical trial in healthy human volunteers.

Salient features of the candidate drug:

- ❖ CDRI 99/373 is a promising option in the prevention and treatment of osteoporosis. Particularly more useful for Osteoporosis accompanying menopause and other estrogen deficiency states.
- ❖ It has excellent antiresorptive activity and has advantage over existing clinically used drugs like raloxifene and bisphosphonates in terms of its efficacy as well as toxicity.
- ❖ It has no/negligible estrogenic profile (Uterotrophic side effect) on genital tract tissue.
- ❖ Compound has low thrombogenic activity in comparison to known drug (Raloxifene).
- ❖ Cost effective due to One pot synthesis protocol.

EOI are invited from interested Pharma Industries for licensing the above candidate drug on Exclusive/Non-exclusive basis for manufacturing & marketing the product. The application including the details of company profile and marketing strategies should reach the undersigned within one (1) month of issuing of this notification. The selected parties shall be called for discussions. The selected party(ies) shall be conducting the required clinicals trials and / or any other studies as per the regulatory requirements in India and outside india on getting license on mutually agreed terms and conditions.

Interested parties may send their Expression of Interest in a sealed cover superscripting "Expression of Interest for 99/373" addressed to the Director, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extn., Sitapur Road, Lucknow - 226 031, UP, India, Email: director@cdri.res.in.